Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Potential candidates for off-label use: Clinicians may consider GLP-1 therapy for women with PCOS who meet the following criteria: Overweight or obesity (particularly BMI 30 kg/m) with PCOS Insulin resistance or impaired glucose tolerance Inadequate response to lifestyle modification and other treatments No contraindications to GLP-1 therapy Not planning pregnancy in the immediate future Contraindications and precautions: GLP-1 receptor agonists are contraindicated in pregnancy and breastfeeding
Genetic and biological factors may play a role in treatment response, though this remains an area of ongoing research
Your provider will discuss whether to continue, adjust, or discontinue semaglutide based on individual circumstances
Use new sterile insulin syringes
Coverage varies by plan, however
